Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Sentinel Framework Should Preclude “Unbridled” Data Mining – Platt

Executive Summary

FDA's nascent electronic post-market drug safety monitoring project - Sentinel - should be designed to investigate only known problems or specific issues raised by spontaneous reports or studies, Harvard University's Richard Platt recommends

You may also be interested in...



Aetna Plans “Clinical Alert” On Plavix Use With PPIs Based On Claims Review

Aetna is developing a clinical alert for physicians and pharmacists to warn about potentially reduced effectiveness for Plavix (clopidogrel) when the antiplatelet drug is used concurrently with a proton pump inhibitor, such as Prilosec (omeprazole) or Nexium (esomeprazole)

Aetna Plans “Clinical Alert” On Plavix Use With PPIs Based On Claims Review

Aetna is developing a clinical alert for physicians and pharmacists to warn about potentially reduced effectiveness for Plavix (clopidogrel) when the antiplatelet drug is used concurrently with a proton pump inhibitor, such as Prilosec (omeprazole) or Nexium (esomeprazole)

E-Prescribing Incentives Offer Model For Electronic Records – CBO’s Orszag

Proponents of the universal adoption of electronic health records might look to follow the "carrot and stick" incentives for electronic prescribing created by the new Medicare Improvements Act, Congressional Budget Office Director Peter Orszag suggests

Related Content

UsernamePublicRestriction

Register

PS049783

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel